<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002286</url>
  </required_header>
  <id_info>
    <org_study_id>TwHF Pilot</org_study_id>
    <nct_id>NCT02002286</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses</brief_title>
  <official_title>Pilot Study: Safety and Efficacy Study of Tripterygium Wilfordii Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LI Taisheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot study to evaluate impact of Tripterygium Wilfordii Hook F (TwHF) on T
      cell immune activation and immune activation in HIV-infected immunological non-responders.
      The investigators aim to evaluate the safety and efficacy profiles of TwHF in HIV
      immunological non-responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators recruited 23 patients from Peking Union Medical College Hospital Outpatient
      clinic. They were all immunological non-responders. Nineteen patients will receive Triptolide
      wilfordii Hook F extract (10mg tid po) plus current cART, while 4 patients will continue
      their current cART. This study will last for 12 months. Patients will be followed up at month
      0, 3, 6, 9, and 12. During each follow-up time point, adverse effects, T cell subsets, T cell
      activation markers and other routine tests will be ordered. The investigators hypothesis that
      TwHF might boost CD4 cell recovery by reducing immune activation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of T cell subsets and immune activation markers</measure>
    <time_frame>12 months</time_frame>
    <description>T cell subsets and activation biomarkers including CD4 count, memory and naive CD4 cell count, and CD38/HLA-DR expression will be monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>12 months</time_frame>
    <description>During follow-up, viral load will also be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>During each follow-up time point, clinical status and adverse effects will also be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>TwHF extract + cART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cART control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continue current cART regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium Wilfordii Hook F extract (TwHF extract)</intervention_name>
    <description>The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.</description>
    <arm_group_label>TwHF extract + cART</arm_group_label>
    <other_name>Triptolide Wilfordii</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cART</intervention_name>
    <description>Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.</description>
    <arm_group_label>TwHF extract + cART</arm_group_label>
    <arm_group_label>cART control</arm_group_label>
    <other_name>Combination antiretroviral therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Continuous antiretroviral therapy &gt; 18 months, and consistent HIV-RNA&lt; 40 copies/mL
             more than 12 months;

          -  18-65 years old;

          -  Male or female;

          -  Good adherence and promise to follow-up;

          -  Inform Consent signed;

          -  CD4 T cells less than 300/ul .

        Exclusion Criteria:

          -  Active opportunistic infection (not stable within 4 weeks 2 weeks ) or AIDS-related
             carcinoma;

          -  Hemoglobin (HGB) &lt; 9 g/dl, white blood cell (WBC) &lt; 2000/ul, granulin (GRN) &lt; 1000
             /ul, platelet (PLT) &lt; 75000 /ul, Cr &gt;1.5x ULN, ALT or AST or alkaline phosphatase
             (ALP) &gt;3x upper limit of normal (ULN), total bilirubin (TBIL) &gt;2x ULN, creatine kinase
             (CK) &gt; 2x ULN;

          -  Pregnant or breastfeeding woman or woman with pregnancy plan;

          -  Active drug-user;

          -  Severe neurological defects;

          -  Active alcohol abuse;

          -  Severe gastrointestinal ulcer .

          -  End-stage disease such as cirrhosis, chronic obstructive pulmonary disease, congestive
             heart failure, recent myocardial ischemia,tumor, etc Those who are undertaking
             steroids, immunomodulator, anti-inflammatory agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisheng Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, Clerici M. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011 Sep 22;118(12):3263-72. doi: 10.1182/blood-2011-01-329060. Epub 2011 May 16.</citation>
    <PMID>21576701</PMID>
  </reference>
  <reference>
    <citation>Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, Brenchley JM, Douek DC. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010 Nov;84(22):12082-6. doi: 10.1128/JVI.01466-10. Epub 2010 Sep 15.</citation>
    <PMID>20844049</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>November 29, 2013</last_update_submitted>
  <last_update_submitted_qc>November 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>LI Taisheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-infected immunological non-responders</keyword>
  <keyword>Tripterygium Wilfordii Hook F</keyword>
  <keyword>Immune activation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

